이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Arrowhead Pharmaceuticals 관리

관리 기준 확인 3/4

Arrowhead Pharmaceuticals' CEO는 Chris Anzalone, Dec2007 에 임명되었습니다 의 임기는 16.5 년입니다. 총 연간 보상은 $ 9.92M, 9.1% 로 구성됩니다. 9.1% 급여 및 90.9% 보너스(회사 주식 및 옵션 포함). 는 R$ 476.54M 가치에 해당하는 회사 주식의 2.99% 직접 소유합니다. 476.54M. 경영진과 이사회의 평균 재임 기간은 각각 6 년과 13.6 년입니다.

주요 정보

Chris Anzalone

최고 경영자

US$9.9m

총 보상

CEO 급여 비율	9.1%
CEO 임기	16.5yrs
CEO 소유권	3.0%
경영진 평균 재임 기간	6yrs
이사회 평균 재임 기간	13.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chris Anzalone 의 보수는 Arrowhead Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$471m
Dec 31 2023	n/a	n/a	-US$297m
Sep 30 2023	US$10m	US$903k	-US$205m
Jun 30 2023	n/a	n/a	-US$181m
Mar 31 2023	n/a	n/a	-US$150m
Dec 31 2022	n/a	n/a	-US$155m
Sep 30 2022	US$12m	US$863k	-US$176m
Jun 30 2022	n/a	n/a	-US$154m
Mar 31 2022	n/a	n/a	-US$112m
Dec 31 2021	n/a	n/a	-US$183m
Sep 30 2021	US$25m	US$837k	-US$141m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$110m
Dec 31 2020	n/a	n/a	-US$103m
Sep 30 2020	US$14m	US$786k	-US$85m
Jun 30 2020	n/a	n/a	-US$24m
Mar 31 2020	n/a	n/a	US$10m
Dec 31 2019	n/a	n/a	US$53m
Sep 30 2019	US$2m	US$674k	US$68m
Jun 30 2019	n/a	n/a	US$46m
Mar 31 2019	n/a	n/a	US$10m
Dec 31 2018	n/a	n/a	-US$29m
Sep 30 2018	US$2m	US$643k	-US$54m
Jun 30 2018	n/a	n/a	-US$54m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	n/a	n/a	-US$35m
Sep 30 2017	US$2m	US$616k	-US$34m

보상 대 시장: Chris 의 총 보상 ($USD 9.92M )은 BR 시장( $USD 1.44M ).

보상과 수익: Chris 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chris Anzalone (55 yo)

16.5yrs

테뉴어

US$9,918,093

보상

Dr. Christopher R. Anzalone, also known as Chris, Ph D., has been the Chief Executive Officer and President at Arrowhead Pharmaceuticals, Inc. since December 1, 2007. He serves as Chief Executive Officer o...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Anzalone	CEO, President & Director	16.5yrs	US$9.92m	2.99% $ 537.3m
Kenneth Myszkowski	Chief Financial Officer	14.3yrs	US$3.12m	0.19% $ 34.1m
Patrick O'Brien	COO, General Counsel & Secretary	9.5yrs	US$3.31m	0.23% $ 41.3m
James Hamilton	Chief of Discovery & Translational Medicine	no data	US$3.05m	0.16% $ 29.6m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	데이터 없음	데이터 없음
Vincent Anzalone	Head of Investor Relations & VP	no data	데이터 없음	데이터 없음
Howard Lovy	Director of Communications	18.8yrs	데이터 없음	데이터 없음
Bruce Given	Chief Medical Scientist	less than a year	US$16.34m	데이터 없음
Mark Seefeld	Head of Toxicology & VP	no data	데이터 없음	데이터 없음
Tracie Oliver	Chief Commercial Officer	2yrs	US$2.97m	0.0073% $ 1.3m
Aaron Tan	Head of Tax	2.4yrs	데이터 없음	데이터 없음
Nadia Meshkova	VP & Treasurer	2.4yrs	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: A2RR34 의 관리팀은 노련하고 경험 (평균 재직 기간 6 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Anzalone	CEO, President & Director	16.5yrs	US$9.92m	2.99% $ 537.3m
Mark Davis	Founder and Founder & Director of Insert Therapeutics Inc & Calando	no data	데이터 없음	데이터 없음
Douglass Given	Chairman of the Board	13.6yrs	US$474.60k	0.11% $ 20.3m
Michael Perry	Independent Lead Director	12.5yrs	US$459.60k	0.074% $ 13.3m
William Waddill	Independent Director	6.4yrs	US$469.60k	0.026% $ 4.8m
Ching-Lung Lai	Member of Hepatitis B Clinical Advisory Board	no data	데이터 없음	데이터 없음
Robert Gish	Chairman of Hepatitis B Clinical Advisory Board	no data	데이터 없음	데이터 없음
Mauro Ferrari	Independent Director	13.8yrs	US$459.60k	0.037% $ 6.6m
Jeffrey Teckman	Member of Alpha-1 Antitrypsin Deficiency Clinical Advisory Board	no data	데이터 없음	데이터 없음
Stephen Locarnini	Member of Hepatitis B Clinical Advisory Board	no data	데이터 없음	데이터 없음
Johnson Lau	Member of Hepatitis B Clinical Advisory Board	no data	데이터 없음	데이터 없음
Carlo Ferrari	Member of Hepatitis B Clinical Advisory Board	no data	데이터 없음	데이터 없음

13.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: A2RR34 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 13.6 년).

Arrowhead Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Recent updates

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics.

Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study

Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline

Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3

Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer

Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE

Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors

Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia

Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령